Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases: Five-year Experience of a Pediatric Tertiary Hospital in Portugal
DOI:
https://doi.org/10.20344/amp.19063Keywords:
Child, Neurocutaneous Syndromes/diagnosis, Neurocutaneous Syndromes/genetics, Neurofibromatoses 1, Outpatient Clinics, Hospital, Tuberous SclerosisAbstract
Introduction: Neurocutaneous syndromes (NCS) are a heterogeneous group of conditions with multiorgan involvement and diverse manifestations, evolving throughout life with significant morbidity. A multidisciplinary approach to NCS patients has been advocated, although a specific model is not yet established. The aim of this study was 1) to describe the organization of the recently created Multidisciplinary Outpatient Clinic of Neurocutaneous Diseases (MOCND) at a Portuguese pediatric tertiary hospital; 2) to share our institutional experience focusing on the most common conditions, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex (TSC); 3) to analyze the advantages of a multidisciplinary center and approach in NCS.
Methods: Retrospective analysis of 281 patients enrolled in the MOCND over the first five years of activity (October 2016 to December 2021), reviewing genetics, family history, clinical features, complications, and therapeutic strategies for NF1 and TSC.
Results: The clinic works weekly with a core team of pediatricians and pediatric neurologists supported by other specialties as needed. Of the 281 patients enrolled, 224 (79.7%) had identifiable syndromes such as NF1 (n = 105), TSC (n = 35), hypomelanosis of Ito (n = 11), Sturge-Weber syndrome (n = 5), and others. In NF1 patients, 41.0% had a positive family history, all manifested café-au-lait macules, 38.1% neurofibromas with 45.0% being large plexiform
neurofibromas. Sixteen were under treatment with selumetinib. Genetic testing was performed in 82.9% of TSC patients with pathogenic variants found in TSC2 gene in 72.4% patients (82.7% if considered contiguous gene syndrome). Family history was positive in 31.4%. All TSC patients presented hypomelanotic macules and fulfilled diagnostic criteria. Fourteen patients were being treated with mTOR inhibitors.
Conclusion: Offering a systematic and multidisciplinary approach to NCS patients enables timely diagnosis, promotes a structured follow-up, and encourages discussion to outline management plans for optimal care to every patient, with significant impact on the quality of life of patients and families.
Downloads
References
Klar N, Cohen B, Lin DD. Neurocutaneous syndromes. Handb Clin Neurol. 2016;135:565-89. DOI: https://doi.org/10.1016/B978-0-444-53485-9.00027-1
Rosser T. Neurocutaneous disorders. Contin Lifelong Learn Neurol. 2018;24:96-129. DOI: https://doi.org/10.1212/CON.0000000000000562
Ruggieri M, Praticò AD. Mosaic neurocutaneous disorders and their causes. Semin Pediatr Neurol. 2015;22:207-33. DOI: https://doi.org/10.1016/j.spen.2015.11.001
Barros FS, Marussi VH, Amaral LL, Da Rocha AJ, Campos CM, Freitas LF, et al. The rare neurocutaneous disorders update on clinical, molecular, and neuroimaging features. Top Magn Reson Imaging. 2018;27:433-62. DOI: https://doi.org/10.1097/RMR.0000000000000185
Ruggieri M, Polizzi A, Marceca GP, Catanzaro S, Praticò AD, Di Rocco C. Introduction to phacomatoses (neurocutaneous disorders) in childhood. Childs Nerv Syst. 2020;36:2229-68. DOI: https://doi.org/10.1007/s00381-020-04758-5
Marjanska A, Jatczak-Gaca A, Wojtkiewicz A, Wysocki M, Styczynski J. Demographical profile and spectrum of multiple malignancies in children and adults with neurocutaneous disorders. Anticancer Res. 2018;38:5453-7. DOI: https://doi.org/10.21873/anticanres.12877
Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50-66. DOI: https://doi.org/10.1016/j.pediatrneurol.2021.07.011
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506-13. DOI: https://doi.org/10.1038/s41436-021-01170-5
Winter PR, Itinteang T, Leadbitter P, Tan ST. PHACE syndrome-clinical features, aetiology and management. Acta Paediatr. 2016;105:145-53. DOI: https://doi.org/10.1111/apa.13242
Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124-33. DOI: https://doi.org/10.1542/peds.2007-3204
Rodríguez AD, Moreno GA, Santo-Domingo YM, Martín AH, Roca JM, Rojas ML, et al. Phenotypic and genetic features in neurofibromatosis type 1 in children. An Pediatr. 2015;83:173-82. DOI: https://doi.org/10.1016/j.anpede.2015.07.015
Sur ML, Armat I, Sur G, Pop DC, Samasca G, Lupan I, et al. Neurofibromatosis in children: actually and perspectives. Children. 2022;9:1-12. DOI: https://doi.org/10.3390/children9010040
Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Arch Craniofacial Surg. 2022;263:6-16. DOI: https://doi.org/10.7181/acfs.2022.00633
García-Romero MT, Parkin P, Lara-Corrales I. Mosaic neurofibromatosis type 1: a systematic review. Pediatr Dermatol. 2016;33:9-17. DOI: https://doi.org/10.1111/pde.12673
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345-56. DOI: https://doi.org/10.1056/NEJMra055323
Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243-54. DOI: https://doi.org/10.1016/j.pediatrneurol.2013.08.001
Rosset C, Netto CB, Ashton-Prolla P. TSC1 and TSC2 gene mutations and their implications for treatment in tuberous sclerosis complex: a review. Genet Mol Biol. 2017;40:69-79. DOI: https://doi.org/10.1590/1678-4685-gmb-2015-0321
Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9:88-100. DOI: https://doi.org/10.1097/GIM.0b013e31803068c7
Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255-65. DOI: https://doi.org/10.1016/j.pediatrneurol.2013.08.002
Back SJ, Andronikou S, Kilborn T, Kaplan BS, Darge K. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome. Pediatr Radiol. 2015;45:386-95. DOI: https://doi.org/10.1007/s00247-014-3147-1
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430-42. DOI: https://doi.org/10.1056/NEJMoa1912735
Merker VL, Knight P, Radtke HB, Yohay K, Ullrich NJ, Plotkin SR, et al. Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis. 2022;17:1-11. DOI: https://doi.org/10.1186/s13023-022-02196-x
Grossen A, Gavula T, Chrusciel D, Evans A, McNall-Knapp R, Taylor A, et al. Multidisciplinary neurocutaneous syndrome clinics: a systematic review and institutional experience. Neurosurg Focus. 2022;52:1-12. DOI: https://doi.org/10.3171/2022.2.FOCUS21776
Kokkinou E, Roka K, Alexopoulos A, Tsina E, Nikas I, Krallis P, et al. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience. Postgrad Med. 2019;131:445-52. DOI: https://doi.org/10.1080/00325481.2019.1659708
DeBella K, Szudek J, Friedman JM. Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105:608-14. DOI: https://doi.org/10.1542/peds.105.3.608
Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet. 2022;141:177-91. DOI: https://doi.org/10.1007/s00439-021-02410-z
Pannu AK, Sharma N. Neurofibromatosis type 1 and disseminated malignant peripheral nerve sheath tumor. QJM. 2017;110:583-4. DOI: https://doi.org/10.1093/qjmed/hcx071
Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75. DOI: https://doi.org/10.1186/1750-1172-7-75
Levin MH, Armstrong GT, Broad JH, Zimmerman R, Bilaniuk LT, Feygin T, et al. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening. Br J Ophthalmol. 2016;100:510-14. DOI: https://doi.org/10.1136/bjophthalmol-2015-306958
Friedrich RE, Nuding MA. Optic pathway glioma and cerebral focal abnormal signal intensity in patients with neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134 affected individuals and a brief review of the literature. Anticancer Res. 2016;36:4095-121.
Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015;167:851-6.e1. DOI: https://doi.org/10.1016/j.jpeds.2015.07.001
Korf BR, Martina Bebin E. Neurocutaneous disorders in children. Pediatr Rev. 2017;38:119-28. DOI: https://doi.org/10.1542/pir.2015-0118
Plasschaert E, Descheemaeker MJ, Van Eylen L, Noens I, Steyaert J, Legius E. Prevalence of autism spectrum disorder symptoms in children with neurofibromatosis type 1. Am J Med Genet Part B Neuropsychiatr Genet. 2015;168:72-80. DOI: https://doi.org/10.1002/ajmg.b.32280
Bissler JJ, Christopher Kingswood J. Renal manifestation of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178:338-47. DOI: https://doi.org/10.1002/ajmg.c.31654
Janssens P, Van Hoeve K, De Waele L, De Rechter S, Claes KJ, Van de Perre E, et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018;33:2085-93. DOI: https://doi.org/10.1007/s00467-018-4003-6
Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 2006;70:1777-82. DOI: https://doi.org/10.1038/sj.ki.5001853
Lu Y, Liu X, Zhang E, Kopras EJ, Smith EP, Astreinidis A, et al. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells. PLoS One. 2020;15:e0228894. DOI: https://doi.org/10.1371/journal.pone.0228894
Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, et al. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study. Nephron. 2016;134:51-8. DOI: https://doi.org/10.1159/000448293
European Medicines Agency. Anexo I - Resumo das características do medicamento - everolimus. Amsterdam; 2010. [cited 2022 Apr 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_pt.pdf.
Franz DN, Budde K, Kingswood JC, Belousova E, Sparagana S, de Vries PJ, et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J Eur Acad Dermatology Venereol. 2018;32:1796-803. DOI: https://doi.org/10.1111/jdv.14964
Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80:574-80. DOI: https://doi.org/10.1212/WNL.0b013e3182815428
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
